EMA: "small increased risk of bladder cancer" with pioglitazone

In patients who respond to pioglitazone, the CHMP concluded that the benefits outweigh the risks | SCIENCE PHOTO LIBRARY
In patients who respond to pioglitazone, the CHMP concluded that the benefits outweigh the risks | SCIENCE PHOTO LIBRARY

A review into the possible increased risk of bladder cancer with pioglitazone has been completed by the MHRA. The results indicated that there is a small increase in risk associated with pioglitazone use.

As a result, pioglitazone is contraindicated in patients with active or historical bladder cancer, or uninvestigated haematuria and all patients should be assessed for risk factors. These include:

  • age
  • current or history of smoking
  • previous pelvic irradiation
  • exposure to certain occupational or chemotherapy agents, for example cyclophosphamide.

Additionally, treatment in the elderly should be carefully considered due to their increased risk of bladder cancer.

In patients who are prescribed pioglitazone, the risk-benefit should be considered after 3–6 months and patients swapped to other treatment (if appropriate).

Two pioglitazone-containing products are available in the UK: pioglitazone alone (Actos) and pioglitazone plus metformin (Competact).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Stop withdrawal of bipolar disorder treatment, health secretary urged

Stop withdrawal of bipolar disorder treatment, health secretary urged

GPs, pharmacists, psychiatrists and patients are calling...

Contraception advice incentive for GPs linked to 'profound' reduction in abortions

Contraception advice incentive for GPs linked to 'profound' reduction in abortions

A scheme offering GPs financial incentives to provide...